Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review

Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sarepta Therapeutics Inc (Sarepta) is discovers and develops unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches to treat rare neuromuscular diseases. The company develops drugs based on its proprietary, highly-differentiated and innovative platform technology, phosphorodiamidate morpholino oligomer (PMO) chemistries. Its first commercial product, Exondys 51 is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. Sareptas key pipeline products using PMO chemistry includes Golodirsen to skip exon 53 of the DMD gene; and Casimersen to skip exon 45 of the DMD gene. Sarepta is headquartered in Cambridge, Massachusetts, the US.

Sarepta Therapeutics Inc Key Recent Developments

May 03,2018: Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments
Apr 10,2018: Advocacy groups urge US government to lower price of costly DMD drug
Mar 01,2018: Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results and Recent Corporate Developments
Dec 05,2017: Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors
Oct 25,2017: Sarepta Therapeutics Announces Third Quarter 2017 Financial Results and Recent Corporate Developments

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Sarepta Therapeutics Inc - Key Facts 5
Sarepta Therapeutics Inc - Key Employees 6
Sarepta Therapeutics Inc - Key Employee Biographies 7
Sarepta Therapeutics Inc - Major Products and Services 8
Sarepta Therapeutics Inc - History 9
Sarepta Therapeutics Inc - Company Statement 12
Sarepta Therapeutics Inc - Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 Company Analysis 14
Sarepta Therapeutics Inc - Business Description 14
Sarepta Therapeutics Inc - Corporate Strategy 15
Sarepta Therapeutics Inc - SWOT Analysis 16
SWOT Analysis - Overview 16
Sarepta Therapeutics Inc - Strengths 16
Sarepta Therapeutics Inc - Weaknesses 17
Sarepta Therapeutics Inc - Opportunities 18
Sarepta Therapeutics Inc - Threats 19
Sarepta Therapeutics Inc - Key Competitors 20
Section 3 Company Financial Ratios 21
Financial Ratios - Capital Market Ratios 21
Financial Ratios - Annual Ratios 22
Performance Chart 24
Financial Performance 24
Financial Ratios - Interim Ratios 25
Financial Ratios - Ratio Charts 26
Section 4 Companys Lifesciences Financial Deals and Alliances 27
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Sarepta Therapeutics Inc, Recent Deals Summary 29
Section 5 Companys Recent Developments 30
May 03, 2018: Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments 30
Apr 10, 2018: Advocacy groups urge US government to lower price of costly DMD drug 33
Apr 10, 2018: Advocacy groups urge US government to lower price of costly DMD drug 34
Mar 01, 2018: Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results and Recent Corporate Developments 35
Dec 05, 2017: Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors 38
Oct 25, 2017: Sarepta Therapeutics Announces Third Quarter 2017 Financial Results and Recent Corporate Developments 39
Sep 25, 2017: Sarepta Therapeutics Appoints Guriqbal S. Basi, Ph.D. as Chief Scientific Officer 41
Jul 19, 2017: Sarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments 42
Jun 27, 2017: Sarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover 44
Jun 27, 2017: Sarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover 45
Section 6 Appendix 46
Methodology 46
Ratio Definitions 46
About GlobalData 50
Contact Us 50
Disclaimer 50

List Of Tables

List of Tables
Sarepta Therapeutics Inc, Key Facts 5
Sarepta Therapeutics Inc, Key Employees 6
Sarepta Therapeutics Inc, Key Employee Biographies 7
Sarepta Therapeutics Inc, Major Products and Services 8
Sarepta Therapeutics Inc, History 9
Sarepta Therapeutics Inc, Subsidiaries 13
Sarepta Therapeutics Inc, Key Competitors 20
Sarepta Therapeutics Inc, Ratios based on current share price 21
Sarepta Therapeutics Inc, Annual Ratios 22
Sarepta Therapeutics Inc, Annual Ratios (Cont...1) 23
Sarepta Therapeutics Inc, Interim Ratios 25
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Sarepta Therapeutics Inc, Recent Deals Summary 29
Currency Codes 46
Capital Market Ratios 46
Equity Ratios 47
Profitability Ratios 47
Cost Ratios 48
Liquidity Ratios 48
Leverage Ratios 49
Efficiency Ratios 49

List Of Figures

List of Figures
Sarepta Therapeutics Inc, Performance Chart (2013 - 2017) 24
Sarepta Therapeutics Inc, Ratio Charts 26
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28

Sarepta Therapeutics Inc (SRPT) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Sarepta Therapeutics Inc (Sarepta) is discovers and develops unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches to treat rare neuromuscular diseases. The company develops drugs based on its

USD 250 View Report

Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review

Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125 View Report

Dimension Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Dimension Therapeutics Inc (Dimension Therapeutics) is a developer of therapeutic products for the treatment of rare diseases associated with liver and genetic mutations. The company develops its product pipeline based

USD 250 View Report

Endonovo Therapeutics Inc (ENDV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Endonovo Therapeutics Inc (Endonovo Therapeutics) is a commercial stage development company that offers non-invasive medical devices and equipment. The companys products include Electroceutical Therapy a FDA-Cleared for the palliative treatment

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available